title: Failure of radiotherapy in acromegaly.
abstract: BACKGROUND
  Recent data has raised skepticism regarding the long-term effectiveness of radiotherapy (RxT) in acromegaly and its role as an ancillary tool to neurosurgery (Tx).
  
  
  METHODS
  We evaluated 72 acromegalic patients previously submitted to RxT. Data were discarded in 23 patients, who were lost to follow-up, operated on after RxT or irradiated with techniques different from external conventional fractionated RxT. Among the remaining 49 (five with mixed GH-prolactin adenoma), 34 were irradiated after surgical failure and 15 as primary treatment. A second cycle of RxT was administered in two.
  
  
  RESULTS
  (i) GH/IGF-I. After a median follow-up of 14 years (range 3-41), normal age-matched IGF-I levels were reached in eight patients (16%) after 10 years, and GH levels <2.5 microg/l in six (12%) after 9 years. The rate of persistently pathological hormonal levels was still 90% at 25 years. All patients with GH/IGF-I normalization had undergone irradiation without any antisecretory drug. Neither basal GH nor tumor size affected the outcome of RxT. In three patients (6%) a relapse/worsening occurred. (ii) Tumor size. Tumor shrank after 8.5 years in 24 patients (49%), in nine of whom during GH-suppressive treatment. Tumor shrinkage was not predictive of hormonal normalization. (iii) Side-effects. Hypopituitarism was diagnosed in four patients (selective in three and global in one) and GH deficiency in one. Three patients had neurological side-effects and meningioma was shown in two patients.
  
  
  CONCLUSIONS
  RxT is unable to cure acromegaly, because it seldom achieves hormonal normalization even after a very prolonged follow-up. Concomitant antisecretory treatment seems to counteract its effects. RxT can still play a role in those patients with large tumor remnants, because of its capacity to shrink tumor size.
authors.affiliation: Division of Endocrinology, Niguarda Hospital, Neurological Institute Carlo Besta, Milan, Italy. renatocozzi@tiscalinet.it
authors.forename: R
authors.initials: R
authors.lastname: Cozzi
authors.forename: M
authors.initials: M
authors.lastname: Barausse
authors.forename: D
authors.initials: D
authors.lastname: Asnaghi
authors.forename: D
authors.initials: D
authors.lastname: Dallabonzana
authors.forename: S
authors.initials: S
authors.lastname: Lodrini
authors.forename: R
authors.initials: R
authors.lastname: Attanasio
mesh_terms: D000172:Acromegaly / Q000532:radiotherapy*; D000236:Adenoma / Q000473:pathology / Q000532:radiotherapy; D000293:Adolescent; D000328:Adult; D000368:Aged; D019583:Dose Fractionation, Radiation; D005260:Female; D019382:Human Growth Hormone / Q000032:analysis / Q000097:blood / Q000378:metabolism; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000032:analysis; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D010911:Pituitary Neoplasms / Q000378:metabolism / Q000473:pathology / Q000532:radiotherapy; D015175:Prolactinoma / Q000473:pathology / Q000532:radiotherapy; D011878:Radiotherapy / Q000009:adverse effects; D012189:Retrospective Studies; D017211:Treatment Failure
chemical_list: D019382:Human Growth Hormone; D007334:Insulin-Like Growth Factor I